In this episode, presented by the Genscript Biotech Global Forum 2025, BioSpace's Head of Insights Lori Ellis and Tom ...

Year-over-year BioSpace data shows there were fewer job postings live on the website in the fourth quarter of 2024, and the ...

“The OECS remains committed to the sustainable development of the region. The health of our environment is key to this, and ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.

The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...

LEQEMBI ® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild ...

This story incorporates reporting fromBoston.com, Philadelphia Inquirer, The Boston Globe, pharmaphorum, Hartford Courant, BioSpace and Yahoo.

DES MOINES, Iowa, Jan. 7, 2025 /PRNewswire/ -- BioSpace, the leading life sciences news and careers site, has announced its 2025 selections for the industry's most promising up-and-coming companies.